Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies

Journal of Veterinary Internal Medicine

Volumn 19, Issue 1, 2005, Pages 81-86

  Kosarek, Carrie E ^a   Kisseberth, William C ^a   Gallant, Stacey L ^a   Couto, C Guillermo ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Anticancer agents; Chemotherapy; Neoplasia; Nucleoside analog; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER REGRESSION; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG SAFETY; DRUG SCREENING; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC MALIGNANCY; MALE; NEUTROPENIA; NONHUMAN; RETINA HEMORRHAGE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DOG DISEASES; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; INFUSIONS, INTRAVENOUS; MALE; NEOPLASMS;

CANIS FAMILIARIS; EMESIS;

EID: 13544269471     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2005)19<81:CEOGID>2.0.CO;2     Document Type: Article

References (25)

1. Storniolo AM, Allerheiligen SRB, and Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997;24(Suppl 7):S7-2-S7-7.
2. Shipley LA, Brown TJ, Cornpropst JD, et al. Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 1992;20:849-855.
3. Caminier GW, Smith CG. Studies of the enzymatic deamination of cytosine arabinoside. I. Biochem Pharmacol 1965;14:1405-1416.
4. Cozzi PJ, Bajorin DF, Tong W, et al. Toxicology and pharmacokinetics of intravesical gemcitabine: A preclinical study in dogs. Clin Cancer Res 1999;5:2629-2637.
5. Chu E, Mota AC, Fogarasi MC. Pharmacology of cancer chemotherapy: Antimetabolites. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2001:388-415.
6. Couto CG. Lymphoma in the cat and dog. In: Nelson RW, Couto CG, eds. Small Animal Internal Medicine, 3rd ed. St. Louis, MO: Mosby; 2003:1122-1132.
7. Couto CG. Leukemias. In: Nelson RW, Couto CG, eds. Small Animal Internal Medicine, 3rd ed. St. Louis, MO: Mosby; 2003:1133-1141.
8. Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: A comparative analysis of randomized trials. Semin Oncol 2002;29(6 Suppl 20):9-16.
9. Depierre A, Westeel V, Jacoulet P. Gemcitabine induction chemotherapy in non-small cell lung cancer. Semin Oncol 2002;29(3 Suppl 9):55-60.
10. Tripathy D. Overview: Gemcitabine as single-agent therapy for advanced breast cancer. Clin Breast Cancer 2002;3(Suppl 1):8-11.
11. Lund B, Neijt JP. Gemcitabine in cisplatin-resistant ovarian cancer. Semin Oncol 1996;23(5 Suppl 10):72-76.
12. Von der Maase H. Gemcitabine-containing regimens in bladder cancer: A new standard of care. Semin Oncol 2001;28(3 Suppl 10): 1-3.
13. Nabhan C, Krett N, Gandi V, et al. Gemcitabine in hematologic malignancies. Curr Opin Oncol 2001;13:514-521.
14. Patel SRR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001;19:3483-3489.
15. Kindler HL, van Meerbeeck JP. The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol 2002;29:70-76.
16. Shewach DS, Lawrence TS. Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 1996;14:257-263.
17. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-498.
18. Roychowdhury DF, Cassidy CA, Peterson P, et al. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 2002;20:311-315.
19. Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis 2002;40:E16.
20. Chun R, Garrett L, MacEwen EG. Cancer chemotherapy. In: Withrow SJ, MacEwen EG, eds. Small Animal Clinical Oncology, 3rd ed. Philadelphia, PA: WB Saunders; 2001:92-118.
21. Thamm, DH, MacEwen EG, Phillips BS, et al. Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia. Cancer Chemother Pharmacol 2002;49:251-255.
22. Sheafor SE, Couto CG, Ward H, et al. Clinical evaluation of methoximorpholino-doxorubicin (FCE 23762) in dogs with spontaneous malignancies. J Vet Intern Med 2000;14:86-89.
23. Banach MJ, Williams GA. Purtscher retinopathy and necrotizing vasculitis with gemcitabine therapy. Arch Ophthalmol 2000;118:726-727.
24. Shingleton BJ, Bienfang DC, Albert DM, et al. Ocular toxicity associated with high-dose carmustine. Arch Opthalmol 1982;100:1766-1772.
25. Johnson DW, Cagnoni PJ, Schossau TM, et al. Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support. Bone Marrow Transplant 1999;24:785-792.